Skip to content

Kanova vs Symphogen

Kanova logo

Kanova

Pioneering advanced therapies in immuno-oncology and autoimmune diseases

2-10 employees · est. 2015

VS
Symphogen logo

Symphogen

188 employees · est. 2000 · Ballerup, Denmark

Symphogen is the older company (2015 vs 2000); Symphogen is the larger of the two.

Side-by-Side Comparison

Kanova Symphogen
Founded
2015 2000 older
Headquarters
Not tracked yet Ballerup, Denmark
Employees
2-10 188 larger
Industry
Biopharma, Health and Wellness, Pharmaceutical Biopharma, Biotechnology, Pharmaceutical
Funding Stage
Series B Debt Financing
Total Funding
$215.00M $314.00M
Funding Rounds
3 10
Taxonomy
BiopharmaceuticalTherapeutic AntibodiesImmuno-oncologyAutoimmune DiseasesAdvanced TherapiesImmunotherapy +4 Biologics DevelopmentAntibodiesOncologyImmune-oncologyR&D StrategyClinical Stages +4
Website
en.kanovabiopharma.com symphogen.com
Kanova logo

About Kanova

Kanova is a biopharmaceutical company founded in 2015 that focuses on developing therapeutic antibodies and innovative combination therapies in immuno-oncology and autoimmune diseases. The company's slogan, "Pioneering advanced therapies in immuno-oncology and autoimmune diseases," reflects its comm...

Symphogen logo

About Symphogen

Symphogen: Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Supporting Servier’s commitment to improve patients health and the R&D strategy within oncology and immun...

Also comparing in this category

Comparing more than these two?

Get Kanova, Symphogen and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does Kanova compare?

A PDF of Kanova and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

Kanova was founded in 2015, with 2-10 employees. Kanova is a biopharmaceutical company founded in 2015 that focuses on developing therapeutic antibodies and innovative combination therapies in immuno-oncology and autoimmune diseases. The company's s. Symphogen was founded in 2000, based in Ballerup, Denmark, with 188 employees. Symphogen: Symphogen A/S, a Servier company and the Centre of Excellence for Antibodies, operates within in research, early clinical stages and CMC biologics development from research to market. Suppo.
Kanova has raised $215.00M and Symphogen $314.00M. Latest stage: Kanova Series B, Symphogen Debt Financing.
Both work in Biopharma and Pharmaceutical and list oncology, cancer treatment and drug development among their focus areas.

Compare Kanova with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Kanova on 12 Sep 2024, and Symphogen on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout